CJC-1295 + Ipamorelin: The Growth Hormone Stack Explained (2026)
Educational guide for research and informational purposes only. Not medical advice.
Growth hormone optimization is one of the most discussed — and most misunderstood — areas in performance science. CJC-1295 and Ipamorelin are two of the most researched growth hormone secretagogues available, and they're almost always discussed together. The reason is simple: they work through different but complementary mechanisms, and stacking them produces a GH signaling profile that neither achieves alone.
This guide covers the science, the distinction between DAC and no-DAC variants, reconstitution math, dosing protocols, and what this stack is actually designed to do.
The Problem This Stack Addresses
Growth hormone secretion naturally declines with age — starting in the mid-20s, accelerating through the 30s and 40s. This decline correlates with reduced sleep quality, slower recovery, shifts in body composition toward fat accumulation and lean mass loss, and metabolic inefficiency.
The conventional answer is exogenous GH — but that approach replaces the body's own production, suppresses endogenous signaling, and carries significant cost and regulatory complexity.
CJC-1295 + Ipamorelin takes a different approach: amplifying the body's own GH output through two complementary signaling pathways, without replacing it.
CJC-1295: The Baseline Elevator
What It Is
CJC-1295 is a synthetic analog of Growth Hormone Releasing Hormone (GHRH) — the endogenous signal that tells the pituitary to produce and release GH. It's been modified from the native GHRH sequence to dramatically extend its half-life and biological activity.
DAC vs No-DAC: The Critical Distinction
There are two versions, and they behave very differently:
| Factor | CJC-1295 with DAC | CJC-1295 without DAC (Mod GRF 1-29) |
|---|---|---|
| Half-life | ~6–8 days | ~30 minutes |
| Dosing frequency | Once weekly | Daily (typically with Ipamorelin) |
| GH effect | Sustained baseline elevation | Acute pulse amplification |
| IGF-1 elevation | Yes — sustained | Minimal independent effect |
| Mechanism | DAC binds albumin → prolonged receptor stimulation | Short burst of GHRH receptor activation |
CJC-1295 with DAC is the version used in most GH optimization protocols for its once-weekly convenience and sustained IGF-1 elevation. CJC-1295 without DAC (also called Mod GRF 1-29) is used daily, typically injected alongside Ipamorelin to amplify acute GH pulses.
View CJC-1295 (with DAC) 5mg Lyophilized →
View CJC-1295 (without DAC) 5mg Lyophilized →
Ipamorelin: The Clean Pulse Generator
What It Is
Ipamorelin is a selective ghrelin receptor (GHS-R) agonist — a growth hormone secretagogue that triggers acute GH pulses from the pituitary. It was specifically developed to produce GH release with minimal stimulation of cortisol, prolactin, or ACTH — the side effects that plagued earlier GHRPs like GHRP-2 and GHRP-6.
Why Ipamorelin Specifically
Compared to older GHRPs:
- Minimal cortisol stimulation (GHRP-2 and GHRP-6 significantly raise cortisol)
- Minimal prolactin elevation
- Clean GH pulse without the hunger/appetite stimulation of GHRP-6
- Well-studied selectivity profile
The result is a cleaner GH pulse — one that more closely resembles physiologic endogenous release rather than a pharmacologic stress response.
View CJC-1295 / Ipamorelin Blend 10mg/10mg →
Why Stack Them: Dual-Mechanism GH Amplification
GH release from the pituitary is governed by two competing signals:
- GHRH (stimulatory) — tells pituitary to produce and release GH
- Somatostatin (inhibitory) — suppresses GH release between pulses
CJC-1295 amplifies the GHRH signal — raising the baseline and the ceiling of GH production. Ipamorelin triggers acute pulses at the ghrelin receptor — a separate pathway that also suppresses somatostatin at the moment of pulsation.
Together: elevated baseline GH environment (CJC-1295 DAC) + clean daily pulses (Ipamorelin) = amplified endogenous GH signaling that more closely mirrors natural youthful physiology. Neither achieves this profile alone.
Reconstitution Math
CJC-1295 with DAC (5mg vial)
| Step | Value |
|---|---|
| Bacteriostatic water added | 2.0 mL |
| Final concentration | 2.5 mg/mL (2,500 mcg/mL) |
| 1 unit (U-100 syringe) | = 25 mcg |
| 40 units | = 1.0 mg |
| 80 units | = 2.0 mg |
Ipamorelin (5mg vial)
| Step | Value |
|---|---|
| Bacteriostatic water added | 3.0 mL |
| Final concentration | ~1.67 mg/mL |
| 1 unit (U-100 syringe) | ≈ 16.7 mcg |
| 6 units | ≈ 100 mcg |
| 12 units | ≈ 200 mcg |
| 15 units | ≈ 250 mcg |
Protocol Reference
CJC-1295 with DAC — Once Weekly
| Phase | Weekly Dose | Units (U-100) | Volume |
|---|---|---|---|
| Standard | 1.0 mg | 40 units | 0.40 mL |
| Aggressive | 2.0 mg | 80 units | 0.80 mL |
Ipamorelin — Once Daily
| Phase | Daily Dose | Units (U-100) | Volume |
|---|---|---|---|
| Starting dose | 100 mcg | 6 units | 0.06 mL |
| Common working dose | 200 mcg | 12 units | 0.12 mL |
| Upper end | 300 mcg | 18 units | 0.18 mL |
Timing: Ipamorelin is most commonly administered pre-bed or in a fasted/low-insulin state to align with natural GH pulse timing. CJC-1295 DAC can be administered on any consistent weekly day.
What This Stack Supports (Educational)
Based on preclinical research and the known mechanisms of GH/IGF-1 signaling, this stack is studied and discussed in the context of:
- Sleep quality — GH is predominantly released during slow-wave sleep; augmenting GH pulse amplitude is associated with deeper sleep architecture
- Recovery from training — IGF-1 elevation supports muscle protein synthesis and tissue repair
- Body composition — GH and IGF-1 both influence fat metabolism and lean mass maintenance
- Metabolic efficiency — sustained IGF-1 has downstream effects on insulin sensitivity and substrate utilization
Important: These are indirect, mechanism-based associations from preclinical and early clinical research. Human clinical trial data for this specific stack at these doses is limited. Effects are cumulative and consistency-dependent — this is not an acute compound.
Common Mistakes
Confusing DAC vs no-DAC dosing frequency. CJC-1295 with DAC is once weekly. CJC-1295 without DAC is daily. These are not interchangeable protocols.
Expecting steroid-like speed. GH secretagogues work through endogenous signaling. Changes in body composition, sleep, and recovery accumulate over weeks to months — not days.
Overdosing Ipamorelin. More frequent dosing does not produce proportionally more benefit once somatostatin rebounds. Standard once-daily dosing is the most studied pattern.
Ignoring the context. GH signaling interacts heavily with sleep, nutrition (especially carbohydrate timing around Ipamorelin doses), and training load. The compound supports the process — it doesn't replace it.
Storage
| State | Temperature | Duration |
|---|---|---|
| Lyophilized (pre-reconstitution) | ≤ −15°C (5°F) | Until expiry |
| Reconstituted | 2–8°C (refrigerated) | 3–4 weeks |
References
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone and its significance. Endocr Rev. 2006.
- Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone. J Clin Endocrinol Metab. 2006.
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998.
- Nass R, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults. Ann Intern Med. 2008.
Educational Disclaimer: This content is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or individualized treatment recommendations. CJC-1295 and Ipamorelin are research peptides not approved by the FDA for human therapeutic use outside of clinical trials. Consult a qualified healthcare provider before using any of the above.
FitAF Performance — Educational content only.
